Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Pediatric high-grade glioma: biologically and clinically in need of new thinking

Tools
- Tools
+ Tools

Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y. J., Gupta, N., Hawkins, C., Hargrave, D., Haas-Kogan, D. A., Jabado, N., Li, X. N., Mueller, S., Nicolaides, T., Packer, R. J., Persson, A. I., Phillips, J. J., Simonds, E. F., Stafford, J. M., Tang, Y. J., Pfister, S. M., Weiss, W. A. (2017) Pediatric high-grade glioma: biologically and clinically in need of new thinking. NEURO-ONCOLOGY, 19 (2). pp. 153-161. ISSN 1522-8517

Full text not available from this repository.

A copy of the full text may be available at: https://academic.oup.com/neuro-oncology/article-lo...

Abstract

High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.

Item Type: Article
Authors (ICR Faculty only): Jones, Chris
All Authors: Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y. J., Gupta, N., Hawkins, C., Hargrave, D., Haas-Kogan, D. A., Jabado, N., Li, X. N., Mueller, S., Nicolaides, T., Packer, R. J., Persson, A. I., Phillips, J. J., Simonds, E. F., Stafford, J. M., Tang, Y. J., Pfister, S. M., Weiss, W. A.
Additional Information: ISI Document Delivery No.: EP3KF Times Cited: 0 Cited Reference Count: 90 Jones, Chris Karajannis, Matthias A. Jones, David T. W. Kieran, Mark W. Monje, Michelle Baker, Suzanne J. Becher, Oren J. Cho, Yoon-Jae Gupta, Nalin Hawkins, Cynthia Hargrave, Darren Haas-Kogan, Daphne A. Jabado, Nada Li, Xiao-Nan Mueller, Sabine Nicolaides, Theo Packer, Roger J. Persson, Anders I. Phillips, Joanna J. Simonds, Erin F. Stafford, James M. Tang, Yujie Pfister, Stefan M. Weiss, William A. 0 OXFORD UNIV PRESS INC CARY NEURO-ONCOLOGY
Uncontrolled Keywords: clinical trials DIPG genomics glioma pediatric INTRINSIC PONTINE GLIOMA CHILDRENS ONCOLOGY GROUP BRAIN-STEM GLIOMA CANCER-STUDY-GROUP PHASE-III TRIAL MALIGNANT GLIOMAS HYPERFRACTIONATED RADIOTHERAPY PILOCYTIC ASTROCYTOMAS THERAPEUTIC TARGETS GENOMIC LANDSCAPE
Research teams: ICR divisions > Molecular Pathology > Glioma Team
Depositing User: Barry Jenkins
Date Deposited: 25 Apr 2017 10:18
Last Modified: 25 Apr 2017 10:18
URI: http://publications.icr.ac.uk/id/eprint/15810

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust